

Meng-Xin Tian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4940391/publications.pdf>

Version: 2024-02-01

32
papers

962
citations

567281

15
h-index

477307

29
g-index

32
all docs

32
docs citations

32
times ranked

1820
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>SIRT</scp> 5 inhibits peroxisomal <scp>ACOX</scp> 1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Reports, 2018, 19, .	4.5	171
2	Destabilization of Fatty Acid Synthase by Acetylation Inhibits <i>De Novo</i> Lipogenesis and Tumor Cell Growth. Cancer Research, 2016, 76, 6924-6936.	0.9	92
3	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget, 2015, 6, 846-861.	1.8	84
4	The nanomechanical signature of liver cancer tissues and its molecular origin. Nanoscale, 2015, 7, 12998-13010.	5.6	75
5	Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia, 2019, 21, 1133-1142.	5.3	44
6	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. International Journal of Oncology, 2016, 49, 2367-2376.	3.3	39
7	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. Oncotarget, 2017, 8, 5135-5148.	1.8	35
8	Cystathionine β -synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. , 2021, 9, e003031.		33
9	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 169-178.	1.5	32
10	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Medicine, 2019, 17, 106.	5.5	31
11	Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology, 2023, 77, 109-123.	7.3	31
12	Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. , 2020, 8, e000501.		29
13	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. Journal of Cancer, 2019, 10, 5575-5584.	2.5	28
14	The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. World Journal of Surgical Oncology, 2016, 14, 131.	1.9	25
15	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. Annals of Translational Medicine, 2020, 8, 487-487.	1.7	25
16	Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. Oncoimmunology, 2020, 9, 1746573.	4.6	21
17	Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Science China Life Sciences, 2019, 62, 1138-1143.	4.9	19
18	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. Journal of Cancer, 2018, 9, 1106-1112.	2.5	16

#	ARTICLE	IF	CITATIONS
19	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1025-1032.	2.5	14
20	Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma. <i>Journal of Cancer</i> , 2020, 11, 5177-5186.	2.5	14
21	Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS ICC applied prediction model. <i>Cancer Science</i> , 2020, 111, 1084-1092.	3.9	14
22	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , 2017, 17, 762.	2.6	12
23	Autophagy activation contributes to glutathione transferase Mu mediated chemoresistance in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 346-352.	1.8	12
24	Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1369-1378.	4.2	12
25	Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 5187-5195.	1.9	12
26	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	6.4	10
27	Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. <i>BMC Cancer</i> , 2020, 20, 642.	2.6	9
28	LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3892-900.	0.5	9
29	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. <i>Aging</i> , 2019, 11, 11111-11123.	3.1	6
30	A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 971-982.	1.7	5
31	Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. <i>BioScience Trends</i> , 2017, 11, 469-474.	3.4	3
32	P-L1 Exploring Pathological Signatures for Predicting Recurrence of Early-stage Hepatocellular Carcinoma Based on Deep Learning. <i>British Journal of Surgery</i> , 2021, 108, .	0.3	0